IDE 397
Alternative Names: GSK-4362676; IDE-397Latest Information Update: 18 Mar 2026
At a glance
- Originator IDEAYA Biosciences
- Developer Amgen; IDEAYA Biosciences
- Class Antineoplastics; Small molecules
- Mechanism of Action MAT2A protein inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Bladder cancer; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer
- Phase I/II Solid tumours; Urogenital cancer
Most Recent Events
- 09 Mar 2026 Pharmacodynamics data form preclinical trial in solid tumours released by IDEAYA Biosciences
- 17 Feb 2026 IDEAYA Biosciences plans to initiate a clinical trial for Solid tumours (Combination therapy) in the second quarter of 2026 (PO)
- 30 Jan 2026 IDEAYA Biosciences has worldwide patent protection for IDE 397